Skip to main content
Erschienen in: Drug Safety 11/2009

01.11.2009 | Review Article

A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours

verfasst von: Dominik Wolf, Holger Rumpold

Erschienen in: Drug Safety | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

Targeting constitutively activated tyrosine kinases, such as BCR-ABL, in chronic myeloid leukaemia (CML) and c-KIT in gastrointestinal stromal tumours (GIST) has substantially changed the clinical management of both diseases. The introduction of imatinib, a tyrosine kinase inhibitor mainly targeting BCR-ABL, c-KIT and PDGFR, has profoundly improved the prognosis of both entities, while being surprisingly well tolerated. This article summarizes recent data on clinical efficacy as well as safety aspects of imatinib for treatment of CML and GIST, including a final benefit-risk assessment. Imatinib induces high rates of cytogenetic and molecular responses in all phases of CML and also has substantial activity in GIST patients. In both diseases, only a few adverse effects, such as musculoskeletal and joint pain, muscle cramps, oedema and gastrointestinal symptoms, occur. Most of these are grade I or II toxicities and generally occur during the early phase of treatment (i.e. within the first 2 years). Thus, in view of the low rates of severe toxicities and the extraordinary efficacy of the drug in both diseases, imatinib represents an oral drug with a high benefit-risk ratio for the treatment of CML and GIST.
Literatur
1.
3.
Zurück zum Zitat Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105(7): 2640–53PubMedCrossRef Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105(7): 2640–53PubMedCrossRef
4.
Zurück zum Zitat Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355(23): 2408–17PubMedCrossRef Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355(23): 2408–17PubMedCrossRef
5.
Zurück zum Zitat Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13(23): 7080–5PubMedCrossRef Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13(23): 7080–5PubMedCrossRef
6.
Zurück zum Zitat Hochhaus A, Druker BJ, Larson RA, et al. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. ASH Annual Meeting Abstracts 2007; 110(11): 25 Hochhaus A, Druker BJ, Larson RA, et al. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. ASH Annual Meeting Abstracts 2007; 110(11): 25
7.
Zurück zum Zitat Baccarani M, Saglio G, Goldman J, et al. European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006 Sep 15; 108(6): 1809–20PubMedCrossRef Baccarani M, Saglio G, Goldman J, et al. European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006 Sep 15; 108(6): 1809–20PubMedCrossRef
8.
Zurück zum Zitat Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharma-cokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111(8): 4022–8PubMedCrossRef Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharma-cokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111(8): 4022–8PubMedCrossRef
9.
Zurück zum Zitat White D, Saunders V, Grigg A, et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007; 25(28): 4445–51PubMedCrossRef White D, Saunders V, Grigg A, et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007; 25(28): 4445–51PubMedCrossRef
10.
Zurück zum Zitat White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110(12): 4064–72PubMedCrossRef White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110(12): 4064–72PubMedCrossRef
11.
Zurück zum Zitat Jiang X, Saw KM, Eaves A, et al. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99(9): 680–93PubMedCrossRef Jiang X, Saw KM, Eaves A, et al. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99(9): 680–93PubMedCrossRef
12.
Zurück zum Zitat Cortes J, Giles F, Salvado AJ, et al. Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT Trial Study Group [abstract]. ASH Annual Meeting Abstracts 2006; 108(11): 2149 Cortes J, Giles F, Salvado AJ, et al. Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT Trial Study Group [abstract]. ASH Annual Meeting Abstracts 2006; 108(11): 2149
13.
Zurück zum Zitat Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103(8): 2873–8PubMedCrossRef Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103(8): 2873–8PubMedCrossRef
14.
Zurück zum Zitat Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg/day of imatinib as initial therapy. Blood 2008; 112(10): 3965–73PubMedCrossRef Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg/day of imatinib as initial therapy. Blood 2008; 112(10): 3965–73PubMedCrossRef
15.
Zurück zum Zitat Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007 Jan 1; 109(1): 58–60PubMedCrossRef Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007 Jan 1; 109(1): 58–60PubMedCrossRef
16.
Zurück zum Zitat Carella AM, Lerma E. Durable responses in chronic mye-loid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission. Ann Hematol 2007 Oct; 86(10): 749–52PubMedCrossRef Carella AM, Lerma E. Durable responses in chronic mye-loid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission. Ann Hematol 2007 Oct; 86(10): 749–52PubMedCrossRef
17.
Zurück zum Zitat Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99(6): 1928–37PubMedCrossRef Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99(6): 1928–37PubMedCrossRef
18.
Zurück zum Zitat Kantarjian H, Talpaz M, O’Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukaemia: comparison with historic experience. Cancer 2005 May 15; 103(10): 2099–108PubMedCrossRef Kantarjian H, Talpaz M, O’Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukaemia: comparison with historic experience. Cancer 2005 May 15; 103(10): 2099–108PubMedCrossRef
19.
Zurück zum Zitat Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99(10): 3530–9PubMedCrossRef Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99(10): 3530–9PubMedCrossRef
20.
Zurück zum Zitat Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99(10): 3547–53PubMedCrossRef Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99(10): 3547–53PubMedCrossRef
21.
Zurück zum Zitat Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22(12): 2176–83PubMedCrossRef Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22(12): 2176–83PubMedCrossRef
22.
Zurück zum Zitat Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment. Blood 2007; 111(3): 1039–43PubMedCrossRef Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment. Blood 2007; 111(3): 1039–43PubMedCrossRef
23.
Zurück zum Zitat Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children’s Oncology Group phase 1 study. Blood 2004; 104(9): 2655–60PubMedCrossRef Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children’s Oncology Group phase 1 study. Blood 2004; 104(9): 2655–60PubMedCrossRef
24.
Zurück zum Zitat Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33(5): 459–65PubMedCrossRef Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33(5): 459–65PubMedCrossRef
25.
Zurück zum Zitat Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438(1): 1–12PubMedCrossRef Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438(1): 1–12PubMedCrossRef
26.
Zurück zum Zitat Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer 2005; 103(4): 821–9PubMedCrossRef Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer 2005; 103(4): 821–9PubMedCrossRef
27.
Zurück zum Zitat Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22(18): 3813–25PubMedCrossRef Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22(18): 3813–25PubMedCrossRef
28.
Zurück zum Zitat Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21(23): 4342–9PubMedCrossRef Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21(23): 4342–9PubMedCrossRef
29.
Zurück zum Zitat Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7(2): 129–41PubMedCrossRef Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7(2): 129–41PubMedCrossRef
30.
Zurück zum Zitat Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347(7): 472–80PubMedCrossRef Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347(7): 472–80PubMedCrossRef
31.
Zurück zum Zitat Blanke CD, Demetri GD, Von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26(4): 620–5PubMedCrossRef Blanke CD, Demetri GD, Von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26(4): 620–5PubMedCrossRef
32.
Zurück zum Zitat Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26(4): 626–32PubMedCrossRef Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26(4): 626–32PubMedCrossRef
33.
Zurück zum Zitat Van Glabbeke MM, Owzar K, Rankin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analyis based on 1,640 patients (pts) [abstract]. J Clin Oncol 2007; 25 (18 Suppl.): 10004 Van Glabbeke MM, Owzar K, Rankin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analyis based on 1,640 patients (pts) [abstract]. J Clin Oncol 2007; 25 (18 Suppl.): 10004
34.
Zurück zum Zitat Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23(24): 5795–804PubMedCrossRef Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23(24): 5795–804PubMedCrossRef
35.
Zurück zum Zitat Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364(9440): 1127–34PubMedCrossRef Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364(9440): 1127–34PubMedCrossRef
36.
Zurück zum Zitat Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373(9669): 1097–104PubMedCrossRef Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373(9669): 1097–104PubMedCrossRef
37.
Zurück zum Zitat Zhan WH. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST [abstract]. China Gastrointestinal Cooperative Group. J Clin Oncol 2007; 25(18S): 10045 Zhan WH. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST [abstract]. China Gastrointestinal Cooperative Group. J Clin Oncol 2007; 25(18S): 10045
38.
Zurück zum Zitat Nilsson B, Sjolund K, Kindblom LG, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96(11): 1656–8PubMedCrossRef Nilsson B, Sjolund K, Kindblom LG, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96(11): 1656–8PubMedCrossRef
39.
Zurück zum Zitat Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year. The French Sarcoma Group. J Clin Oncol 2007; 25(9): 1107–13PubMedCrossRef Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year. The French Sarcoma Group. J Clin Oncol 2007; 25(9): 1107–13PubMedCrossRef
40.
Zurück zum Zitat Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99(1): 42–7PubMedCrossRef Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99(1): 42–7PubMedCrossRef
41.
Zurück zum Zitat Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26(33): 5360–7PubMedCrossRef Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26(33): 5360–7PubMedCrossRef
42.
Zurück zum Zitat Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42(8): 1093–103PubMedCrossRef Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42(8): 1093–103PubMedCrossRef
43.
Zurück zum Zitat Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST). Update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 Suppl. 2: S1–29PubMed Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST). Update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 Suppl. 2: S1–29PubMed
44.
Zurück zum Zitat Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 Suppl. 2: ii35–8PubMedCrossRef Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 Suppl. 2: ii35–8PubMedCrossRef
45.
Zurück zum Zitat O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348(11): 994–1004PubMedCrossRef O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348(11): 994–1004PubMedCrossRef
46.
Zurück zum Zitat Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12(8): 908–16PubMedCrossRef Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12(8): 908–16PubMedCrossRef
47.
Zurück zum Zitat Atallah E, Durand JB, Kantarjian H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110(4): 1233–7PubMedCrossRef Atallah E, Durand JB, Kantarjian H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110(4): 1233–7PubMedCrossRef
48.
Zurück zum Zitat Fitter S, Dewar AL, Kostakis P, et al. Long term imatinib therapy promotes bone formation in CML patients. Blood 2007; 111(5): 2538–47PubMedCrossRef Fitter S, Dewar AL, Kostakis P, et al. Long term imatinib therapy promotes bone formation in CML patients. Blood 2007; 111(5): 2538–47PubMedCrossRef
49.
Zurück zum Zitat Fabarius A, Haferlach C, Muller MC, et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007; 92(6): 834–7PubMedCrossRef Fabarius A, Haferlach C, Muller MC, et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007; 92(6): 834–7PubMedCrossRef
50.
Zurück zum Zitat van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358(9291): 1421–3PubMedCrossRef van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358(9291): 1421–3PubMedCrossRef
52.
Zurück zum Zitat Ault P, Kantarjian H, O’Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006; 24(7): 1204–8PubMedCrossRef Ault P, Kantarjian H, O’Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006; 24(7): 1204–8PubMedCrossRef
53.
54.
Zurück zum Zitat Choudhary DR, Mishra P, Kumar R, et al. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol 2006; 17(1): 178–9PubMedCrossRef Choudhary DR, Mishra P, Kumar R, et al. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol 2006; 17(1): 178–9PubMedCrossRef
55.
Zurück zum Zitat Bazarbashi MS, Smith MR, Karanes C, et al. Successful management of Ph chromosome chronic myelogenous leukemia with leukapheresis during pregnancy. Am J Hematol 1991; 38(3): 235–7PubMedCrossRef Bazarbashi MS, Smith MR, Karanes C, et al. Successful management of Ph chromosome chronic myelogenous leukemia with leukapheresis during pregnancy. Am J Hematol 1991; 38(3): 235–7PubMedCrossRef
56.
Zurück zum Zitat Mubarak AA, Kakil IR, Awidi A, et al. Normal outcome of pregnancy in chronic myeloid leukemia treated with inter-feron-alpha in 1st trimester: report of 3 cases and review of the literature. Am J Hematol 2002; 69(2): 115–8PubMedCrossRef Mubarak AA, Kakil IR, Awidi A, et al. Normal outcome of pregnancy in chronic myeloid leukemia treated with inter-feron-alpha in 1st trimester: report of 3 cases and review of the literature. Am J Hematol 2002; 69(2): 115–8PubMedCrossRef
57.
Zurück zum Zitat Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007; 27(4): 241–3PubMedCrossRef Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007; 27(4): 241–3PubMedCrossRef
58.
Zurück zum Zitat DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231(1): 51–8PubMedCrossRef DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231(1): 51–8PubMedCrossRef
59.
Zurück zum Zitat Gold JS, van der Zwan SM, Gonen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007; 14(1): 134–42PubMedCrossRef Gold JS, van der Zwan SM, Gonen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007; 14(1): 134–42PubMedCrossRef
60.
Zurück zum Zitat Rossi CR, Mocellin S, Mencarelli R, et al. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer 2003; 107(2): 171–6PubMedCrossRef Rossi CR, Mocellin S, Mencarelli R, et al. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer 2003; 107(2): 171–6PubMedCrossRef
Metadaten
Titel
A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours
verfasst von
Dominik Wolf
Holger Rumpold
Publikationsdatum
01.11.2009
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 11/2009
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/11314600-000000000-00000

Weitere Artikel der Ausgabe 11/2009

Drug Safety 11/2009 Zur Ausgabe